A Nizoral, Extina, Xolegel, Kuric, Ketoconazole CEP of the European Pharmacopoeia monograph is often referred to as a Nizoral, Extina, Xolegel, Kuric, Ketoconazole Certificate of Suitability (COS). The purpose of a Nizoral, Extina, Xolegel, Kuric, Ketoconazole CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Nizoral, Extina, Xolegel, Kuric, Ketoconazole EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Nizoral, Extina, Xolegel, Kuric, Ketoconazole to their clients by showing that a Nizoral, Extina, Xolegel, Kuric, Ketoconazole CEP has been issued for it. The manufacturer submits a Nizoral, Extina, Xolegel, Kuric, Ketoconazole CEP (COS) as part of the market authorization procedure, and it takes on the role of a Nizoral, Extina, Xolegel, Kuric, Ketoconazole CEP holder for the record. Additionally, the data presented in the Nizoral, Extina, Xolegel, Kuric, Ketoconazole CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Nizoral, Extina, Xolegel, Kuric, Ketoconazole DMF.
A Nizoral, Extina, Xolegel, Kuric, Ketoconazole CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Nizoral, Extina, Xolegel, Kuric, Ketoconazole CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Nizoral, Extina, Xolegel, Kuric, Ketoconazole suppliers with CEP (COS) on PharmaCompass.